Per Endpoints, Elevar's Lyrfigtu wins first FDA nod in FGFR2 bile duct cancer

Elevar Therapeutics won its first FDA approval on 23 September 2026, when — per Endpoints News — the agency cleared Lyrfigtu (lirafugratinib) as a second-line treatment for cholangiocarcinoma carrying an FGFR2 fusion or other rearrangement ^[1]. Elevar's own release states the same indication and second-line setting ^[2], and Oncology News Central carried the approval the same day ^[3]. For a bile duct cancer diagnosed in about 8,000 Americans a year ^[1], this puts an FGFR2-selective option on-label in a rare, historically undertreated tumor.

Why it matters

The asset is not new to oncology developers. Lyrfigtu is Relay Therapeutics' former RLY-4008, an FGFR2-selective inhibitor Relay licensed to Elevar in an exclusive global agreement executed in December 2024 ^[4]. The commercial handoff was deliberate: Relay disclosed in November 2024 that the FDA had steered it to file a cholangiocarcinoma NDA first, with a tumor-agnostic supplemental filing for FGFR2 fusions to follow, and that it would seek a global commercialization partner while prioritizing its PI3Kα program ^[5]. Read against that plan, this approval is the first, narrower step of a sequenced strategy — and the broader tumor-agnostic FGFR2 filing Relay described appears to remain the intended next act, though the dossier does not confirm its current status.

For Elevar, a majority-owned subsidiary of HLB Co., Ltd. ^[2], the milestone converts a licensed-in molecule into a commercial-stage franchise and a first regulatory scalp.

The regulatory clock

Approval landed on 23 September, four days ahead of that target ^[1]. Korea Biomedical Review reported the review had entered its final stage by 24 July 2026 ^[8]. The next dated catalyst sits in Europe: Elevar filed a marketing authorization application with the EMA on 15 September 2026 for advanced or metastatic FGFR2 fusion or rearrangement cholangiocarcinoma ^[9], a step OncLive also reported ^[10]. The dossier carries no EMA review clock or target opinion date, so Prognyx cannot bound when a CHMP opinion would land — that is the open EU question, not a decision.

The competitive read

The FDA has shown appetite for biomarker-defined bile duct niches. In May 2026 it approved Bizengri (zenocutuzumab-zbco) for NRG1 fusion-positive cholangiocarcinoma ^[11] — a different target and drug, cited here only as landscape. Lyrfigtu extends that pattern to the FGFR2 fusion subset, where Elevar now holds an on-label, second-line, selective inhibitor. One registry note for anyone screening databases rather than the news: ChEMBL still lists the compound at maximum clinical phase 2.0 ^[12], a lag behind the approval record, not a contradiction of it.

What to watch

• The EMA decision on the 15 September 2026 application ^[9] — the ex-US sizing hinges on it.
• The tumor-agnostic FGFR2 supplemental filing Relay described ^[5], if Elevar carries it forward.
• Label specifics — dosing, line of therapy wording, safety — once the approved US label is public.

The now-what

For FGFR2-focused developers, the benchmark just moved: a selective inhibitor now defines the on-label second-line comparator in cholangiocarcinoma, and pipeline positioning should be measured against it rather than against chemotherapy alone. For business development, HLB/Elevar shifts from a clinical licensee to a commercial-stage counterparty with a live EU filing. For anyone modeling the FGFR2 franchise, the tumor-agnostic pathway is the value lever to track next.

What Prognyx could not verify

The pivotal trial behind the approval — its ClinicalTrials.gov identifier and recruitment status — could not be confirmed from public records as of this briefing. The approved US label language, dosing and safety details are not yet in hand; nor is an official FDA.gov approval notice, leaving the event supported by press and company reporting. The EU application's outcome is unknown. And two HUTCHMED SEC filings referencing lirafugratinib are unreadable in the provided excerpts, so that company's role, if any, cannot be characterized.

Verdict: a confirmed niche threat for FGFR2-targeting programs — act within the next one to two quarters, before the EU decision and any tumor-agnostic filing widen the label.